公司資料
SeaStar Medical 股價、新聞與催化劑
- 股票代碼:
- ICU
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.25 USD (+2.20%)
收盤價
最後更新: 2026年8月17日
14.1M USD
市值
股價為何變動
As of Aug 17, 2026, ICU closed up 2.20% at $3.25. No new same-company headline was identified in the current news window.
公司概覽
Organ-Failure Immunomodulation Company
SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.
Selective Cytopheretic Device
The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune cells.
QUELIMMUNE
QUELIMMUNE is authorized for pediatric acute kidney injury and is being adopted by children’s hospitals under a Humanitarian Device Exemption.
Adult AKI Program
The pivotal NEUTRALIZE-AKI trial is evaluating the SCD in adults with acute kidney injury requiring continuous renal replacement therapy.
未來催化劑
- Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
- SeaStar plans to begin submitting PMA modules to the FDA as the adult AKI program progresses, with a potential full PMA filing in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。